330 related articles for article (PubMed ID: 27125213)
1. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease.
Emoto T; Yamashita T; Kobayashi T; Sasaki N; Hirota Y; Hayashi T; So A; Kasahara K; Yodoi K; Matsumoto T; Mizoguchi T; Ogawa W; Hirata KI
Heart Vessels; 2017 Jan; 32(1):39-46. PubMed ID: 27125213
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Gut Microbiota in Coronary Artery Disease Patients: a Possible Link between Gut Microbiota and Coronary Artery Disease.
Emoto T; Yamashita T; Sasaki N; Hirota Y; Hayashi T; So A; Kasahara K; Yodoi K; Matsumoto T; Mizoguchi T; Ogawa W; Hirata K
J Atheroscler Thromb; 2016 Aug; 23(8):908-21. PubMed ID: 26947598
[TBL] [Abstract][Full Text] [Related]
3. Comparison between terminal-restriction fragment length polymorphism (T-RFLP) and quantitative culture for analysis of infants' gut microbiota.
Sjöberg F; Nowrouzian F; Rangel I; Hannoun C; Moore E; Adlerberth I; Wold AE
J Microbiol Methods; 2013 Jul; 94(1):37-46. PubMed ID: 23583598
[TBL] [Abstract][Full Text] [Related]
4. Dysbiosis signatures of gut microbiota in coronary artery disease.
Zhu Q; Gao R; Zhang Y; Pan D; Zhu Y; Zhang X; Yang R; Jiang R; Xu Y; Qin H
Physiol Genomics; 2018 Oct; 50(10):893-903. PubMed ID: 30192713
[TBL] [Abstract][Full Text] [Related]
5. Data mining analysis of terminal restriction fragment length polymorphism shows geographical differences in the human gut microbiota.
Andoh A; Kobayashi T; Kuzuoka H; Suzuki Y; Matsui T; Nakamura S; Matsumoto T; Fujiyama Y; Bamba T
Biomed Rep; 2013 Jul; 1(4):559-562. PubMed ID: 24648986
[TBL] [Abstract][Full Text] [Related]
6. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses.
Kasai C; Sugimoto K; Moritani I; Tanaka J; Oya Y; Inoue H; Tameda M; Shiraki K; Ito M; Takei Y; Takase K
Oncol Rep; 2016 Jan; 35(1):325-33. PubMed ID: 26549775
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the gut microbiome and metabolism with coronary artery disease severity.
Liu H; Chen X; Hu X; Niu H; Tian R; Wang H; Pang H; Jiang L; Qiu B; Chen X; Zhang Y; Ma Y; Tang S; Li H; Feng S; Zhang S; Zhang C
Microbiome; 2019 Apr; 7(1):68. PubMed ID: 31027508
[TBL] [Abstract][Full Text] [Related]
8. Effect of Resistant Starch on the Gut Microbiota and Its Metabolites in Patients with Coronary Artery Disease.
Yoshida N; Sasaki K; Sasaki D; Yamashita T; Fukuda H; Hayashi T; Tabata T; Osawa R; Hirata KI; Kondo A
J Atheroscler Thromb; 2019 Aug; 26(8):705-719. PubMed ID: 30587666
[TBL] [Abstract][Full Text] [Related]
9. Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipide-treated mice.
Imaeda H; Fujimoto T; Takahashi K; Kasumi E; Fujiyama Y; Andoh A
Digestion; 2012; 86(3):250-7. PubMed ID: 22964750
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing.
Kasai C; Sugimoto K; Moritani I; Tanaka J; Oya Y; Inoue H; Tameda M; Shiraki K; Ito M; Takei Y; Takase K
BMC Gastroenterol; 2015 Aug; 15():100. PubMed ID: 26261039
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Gut Microbiota in Patients With Diabetes Determined by Data Mining Analysis of Terminal Restriction Fragment Length Polymorphisms.
Nakamura Y; Nagai Y; Kobayashi T; Furukawa K; Oikawa Y; Shimada A; Tanaka Y
J Clin Med Res; 2019 Jun; 11(6):401-406. PubMed ID: 31143306
[TBL] [Abstract][Full Text] [Related]
12. Coronary artery disease is associated with an altered gut microbiome composition.
Toya T; Corban MT; Marrietta E; Horwath IE; Lerman LO; Murray JA; Lerman A
PLoS One; 2020; 15(1):e0227147. PubMed ID: 31995569
[TBL] [Abstract][Full Text] [Related]
13. Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms.
Andoh A; Kobayashi T; Kuzuoka H; Tsujikawa T; Suzuki Y; Hirai F; Matsui T; Nakamura S; Matsumoto T; Fujiyama Y
Biomed Rep; 2014 May; 2(3):370-373. PubMed ID: 24748976
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota and Coronary Artery Disease.
Yamashita T; Emoto T; Sasaki N; Hirata KI
Int Heart J; 2016 Dec; 57(6):663-671. PubMed ID: 27818484
[TBL] [Abstract][Full Text] [Related]
15. Terminal restriction fragment length polymorphism analysis of the gut microbiota profiles of pediatric patients with inflammatory bowel disease.
Aomatsu T; Imaeda H; Fujimoto T; Takahashi K; Yoden A; Tamai H; Fujiyama Y; Andoh A
Digestion; 2012; 86(2):129-35. PubMed ID: 22846404
[TBL] [Abstract][Full Text] [Related]
16. The gut microbiota-related metabolite phenylacetylglutamine associates with increased risk of incident coronary artery disease.
Ottosson F; Brunkwall L; Smith E; Orho-Melander M; Nilsson PM; Fernandez C; Melander O
J Hypertens; 2020 Dec; 38(12):2427-2434. PubMed ID: 32665522
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction patients different from stable coronary artery disease.
Dong C; Yang Y; Wang Y; Hu X; Wang Q; Gao F; Sun S; Liu Q; Li L; Liu J; Tang Y; Zhang S; Wu C; Zhu H
J Adv Res; 2023 Apr; 46():101-112. PubMed ID: 35750287
[TBL] [Abstract][Full Text] [Related]
18. Optimization of terminal restriction fragment polymorphism (TRFLP) analysis of human gut microbiota.
Li F; Hullar MA; Lampe JW
J Microbiol Methods; 2007 Feb; 68(2):303-11. PubMed ID: 17069911
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota and Environment in Coronary Artery Disease.
Piccioni A; de Cunzo T; Valletta F; Covino M; Rinninella E; Raoul P; Zanza C; Mele MC; Franceschi F
Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33923612
[TBL] [Abstract][Full Text] [Related]
20. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.
Andoh A; Sakata S; Koizumi Y; Mitsuyama K; Fujiyama Y; Benno Y
Inflamm Bowel Dis; 2007 Aug; 13(8):955-62. PubMed ID: 17455205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
